CytomX Therapeutics, Inc. (CTMX)

Market Cap	50.32M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
Shares Out	80.10M
EPS (ttm)	0.38
PE Ratio	1.66
Forward PE	2.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	830,991
Open	0.6030
Previous Close	0.6166
Day's Range	0.5906 - 0.6306
52-Week Range	0.5600 - 5.8500
Beta	1.04
Analysts	Buy
Price Target	5.77 (+818.5%)
Earnings Date	Mar 6, 2025

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBO...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX
• Website: https://www.cytomx.com

Analyst Forecast

According to 6 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is $5.77, which is an increase of 818.50% from the latest price.

Price Target

$5.77

(818.50% upside)

Analyst Consensus: Buy